ARCHIVES

Mass. Law Requires Reimbursement For Off-Label Cancer Drugs

This article is from The Cancer Letter archive.

Vol. 19 No. 04 | January 22, 1993

Download PDF Visit The Full Archive

Related Articles

Barnett Kramer Next Director Of NCI Division of Cancer Prevention

July 29, 2011

In Congress: Could NCI Make Use Of Increase? Porter Asks; “We Can Handle It Well,” Klausner Replies

April 3, 1998

Cancer Letter Adds Associate Editor

July 19, 1985

Upon, Panel Lean To Anecdotal Laetrile Study

August 12, 1977

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

NCI Director Klausner Resigns To Head Institute Begun By AOL Chairman Case.

September 14, 2001